Tetrathiomolybdate sensitizes ovarian cancer cells to anticancer drugs doxorubicin, fenretinide, 5-fluorouracil and mitomycin C
Open Access
- 13 April 2012
- journal article
- research article
- Published by Springer Nature in BMC Cancer
- Vol. 12 (1) , 147
Abstract
Our recent study showed that tetrathiomolybdate (TM), a drug to treat copper overload disorders, can sensitize drug-resistant endometrial cancer cells to reactive oxygen species (ROS)-generating anticancer drug doxorubicin. To expand these findings in the present study we explore TM efficacy in combination with a spectrum of ROS-generating anticancer drugs including mitomycin C, fenretinide, 5-fluorouracil and doxorubicin in ovarian cancer cells as a model system. The effects of TM alone or in combination with doxorubicin, mitomycin C, fenretinide, or 5-fluorouracil were evaluated using a sulforhodamine B assay. Flow cytometry was used to detect the induction of apoptosis and ROS generation. Immunoblot analysis was carried out to investigate changes in signaling pathways. TM potentiated doxorubicin-induced cytotoxicity and modulated key regulators of apoptosis (PARP, caspases, JNK and p38 MAPK) in SKOV-3 and A2780 ovarian cancer cell lines. These effects were linked to the increased production of ROS, as shown in SKOV-3 cells. ROS scavenging by ascorbic acid blocked the sensitization of cells by TM. TM also sensitized SKOV-3 to mitomycin C, fenretinide, and 5-fluorouracil. The increased cytotoxicity of these drugs in combination with TM was correlated with the activity of ROS, loss of a pro-survival factor (e.g. XIAP) and the appearance of a pro-apoptotic marker (e.g. PARP cleavage). Our data show that TM increases the efficacy of various anticancer drugs in ovarian cancer cells in a ROS-dependent manner.Keywords
This publication has 46 references indexed in Scilit:
- Enhancement of the efficacy of mitomycin C-mediated apoptosis in human colon cancer cells with RNAi-based thioredoxin reductase 1 deficiencyExperimental and Therapeutic Medicine, 2011
- Enhancing Tumor-Specific Uptake of the Anticancer Drug Cisplatin with a Copper ChelatorCancer Cell, 2010
- A Phase II Trial of Tetrathiomolybdate After Surgery for Malignant Mesothelioma: Final ResultsThe Annals of Thoracic Surgery, 2008
- The role of p38 MAPK and JNK in Arsenic trioxide‐induced mitochondrial cell death in human cervical cancer cellsJournal of Cellular Physiology, 2008
- Reactive oxygen species: Role in the development of cancer and various chronic conditionsJournal of Carcinogenesis, 2006
- Regulation and interplay of apoptotic and non‐apoptotic cell deathThe Journal of Pathology, 2005
- Fenretinide induces sustained‐activation of JNK/p38 MAPK and apoptosis in a reactive oxygen species‐dependent manner in neuroblastoma cellsInternational Journal of Cancer, 2004
- Phase II trial of tetrathiomolybdate in patients with advanced kidney cancer.2003
- POTENTIATION OF DOXORUBICIN CYTO-TOXICITY BY BUTHIONINE SULFOXIMINE IN MULTIDRUG-RESISTANT HUMAN-BREAST TUMOR-CELLS1989
- Clinical trials of mitomycin C, a new antitumor antibiotic; preliminary report of results obtained in 82 consecutive cases in the field of general surgery.1958